anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: dental enamel is purified or treated with the help of application. The process is carried out consequently with the help of two compositions, interval being not less 60 s. The formed composition contains calcium nitrate, sodium carboxymethylcellulose, antiseptic agent, odorant and water. Other composition contains ammonium dihydrophosphate, sodium carboxymethylcellulose, dye, antiseptic agent, odorant and water. Quantities of all the components are within definite ranges. Said treatment is carried out twice a day, treatment course is 30 days. EFFECT: improves efficiency of dental enamel remineralization.
For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
AIMS: Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular (CV) diseases. Dysregulated pro-apoptotic ceramide synthesis reduces β-cell insulin secretion, thereby promoting hyperglycaemic states that may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor CV outcomes. Sirtuin-1 (SIRT1) is a NAD + -dependent deacetylase that protects against pancreatic β-cell dysfunction; however, systemic levels are decreased in obese-T2D mice and may promote pro-apoptotic ceramide synthesis and hyperglycaemia. Herein, we aimed to assess the effects of restoring circulating SIRT1 levels to prevent metabolic imbalance in obese and diabetic mice.
METHODS AND RESULTS: Circulating SIRT1 levels were reduced in obese-diabetic mice (db/db) as compared to age-matched non-diabetic db/+ controls. Restoration of SIRT1 plasma levels with recombinant murine SIRT1 for 4 weeks prevented body weight gain and improved glucose tolerance, insulin sensitivity, and vascular function in mice models of obesity and T2D. Untargeted lipidomics revealed that SIRT1 restored insulin secretory function of β-cells by reducing synthesis and accumulation of pro-apoptotic ceramides. Molecular mechanisms involved direct binding to and deacetylation of Toll-like receptor 4 (TLR4) by SIRT1 in β-cells, thereby decreasing the rate-limiting enzymes of sphingolipid synthesis SPTLC1/2 via AKT/NF-κB. Among patients with T2D, those with high baseline plasma levels of SIRT1 prior to metabolic surgery displayed restored β-cell function (HOMA2-β) and were more likely to have T2D remission during follow-up.
CONCLUSION: Acetylation of TLR4 promotes β-cell dysfunction via ceramide synthesis in T2D, which is blunted by systemic SIRT1 replenishment. Hence, restoration of systemic SIRT1 may provide a novel therapeutic strategy to counteract toxic ceramide synthesis and mitigate CV complications of T2D.
According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
###  Mechanism of Action

Fluconazole is a highly selective inhibitor of fungal cytochrome P450 dependent enzyme lanosterol 14-α-demethylase. This enzyme functions to convert lanosterol to ergosterol. The subsequent loss of normal sterols correlates with the accumulation of 14-α-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.

###  Resistance

A potential for development of resistance to fluconazole is well known. Fungal isolates exhibiting reduced susceptibility to other azoles may also show reduced susceptibility to fluconazole. The frequency of drug resistance development for the various fungi for which this drug is indicated is not known.

Fluconazole resistance may arise from a modification in the quality or quantity of the target enzyme (lanosterol 14-α-demethylase), reduced access to the drug target, or some combination of these mechanisms.

Point mutations in the gene ( ERG11) encoding for the target enzyme lead to an altered target with decreased affinity for azoles. Overexpression of ERG11results in the production of high concentrations of the target enzyme, creating the need for higher intracellular drug concentrations to inhibit all of the enzyme molecules in the cell. 

The second major mechanism of drug resistance involves active efflux of fluconazole out of the cell through the activation of two types of multidrug efflux transporters; the major facilitators (encoded by MDRgenes) and those of the ATP-binding cassette superfamily (encoded by CDRgenes). Upregulation of the MDRgene leads to fluconazole resistance, whereas, upregulation of CDRgenes may lead to resistance to multiple azoles. 

Resistance in Candida glabratausually includes upregulation of CDRgenes resulting in resistance to multiple azoles. For an isolate where the minimum inhibitory concentration (MIC) is categorized as Intermediate (16 to 32 mcg/mL), the highest fluconazole dose is recommended.
Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
Although rarely fatal, complications of ventral midline laparotomy incision in equine patients increase hospitalization cost and duration and may jeopardize return to athletic function. Therefore, many techniques have been developed to reduce their occurrence and expedite their resolution when they occur. Our technique of celiotomy incision closure includes the use of tension sutures (vertical U mattress) of polyglactin 910 on the linea alba, which is then apposed by polyglactin 910 interrupted sutures or a simple continuous pattern suture with a stop midway before routine closure of the superficial layers. The celiotomy incision is protected by an elastic bandage during the immediate postoperative period. This technique has been associated with favorable results: 5.3% confirmed incisional infections after a single celiotomy and 26.7% after repeat celiotomy. The overall incisional complication (serous/sanguineous discharge, hematoma, infection, hernia formation, and complete wound breakdown) occurrence was 9.5% and 33.3% after single and repeat laparotomy, respectively. In cases considered more susceptible to infection (early relaparotomy or laparotomy incisions longer than 30 cm), negative pressure therapy was found easy to apply on closed incisions. No detrimental effects were observed. However, the potential prophylactic benefit of this therapy needs to be confirmed in a larger group. In infected laparotomy wounds requiring drainage, the use of negative pressure therapy seemed to have a positive effect on the formation of granulation tissue. However, there was no control group to allow statistical confirmation. Finally, one case of complete breakdown of the laparotomy incision was managed by stainless steel retention sutures, the application of negative pressure therapy, and a hernia belt. At re-evaluation 15 months post-surgery, several small hernias were detected, but the horse had returned to his previous level of sports performance and had not shown any episode of colic.
The survey will be re-circulated a minimum of three, and maximum of four rounds, with an aim for a minimum of 30 participants and response rate of greater than 70 percent per round. The results will be collected and collated at each round to determine a consensus amongst shoulder specialists for further review. This information will be used to guide the treatment protocol in phase two.
The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of p amyloid versus subjects without p-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) stands as a significant contributor to global mortality rates. Presently, there exists a dearth of effective anti-fibrotic treatments for this condition. While itraconazole (ITR) has exhibited potential in mitigating pulmonary fibrosis, its oral administration is hampered by unfavorable pharmacokinetics, which elevate the risk of adverse reactions, thus limiting its clinical utility.
METHODS: An inhalable formulation of ITR were engineered which aimed at enhancing its pulmonary dispersion. First, pharmacokinetics were conducted to investigate the blood concentration and tissue residue of ITR after inhalation administration. In addition, bleomycin induced mouse pulmonary fibrosis model was used to compare the therapeutic effects of ITR administered by inhalation and intragastric administration. Finally, single-cell RNA sequencing (scRNAseq) was used to explore the mechanism of ITR inhalation administration.
RESULTS: We found that a large amount of drugs accumulated in the lung tissue for a long time after inhalation administration, thus maximizing the therapeutic effect of drugs. Inhalation of ITR daily at for 21 days significantly attenuated bleomycin-induced lung fibrosis and inflammation in murine models. Additionally, our findings revealed that ITR inhalation diminished the proportion of diseased fibroblasts while promoting reparative fibroblast populations in the murine model. Furthermore, it effectively reversed the proportion of activated phagocytic macrophages. Mechanistically, ITR inhalation exerted its effects by regulating SPP1 and C3 signaling pathway pivotal in the interaction between phagocytic macrophages and diseased fibroblasts.
CONCLUSIONS: These insights into the molecular mechanisms underlying ITR's therapeutic effects on IPF underscore the favorable pharmacokinetic profile conferred by inhalation, thus presenting a promising formulation poised for clinical translation.
Rolling recruitment for the study. Participants will be randomized into one of three treatment arms. All treatment arms will undergo physical \& cognitive testing prior to whole-brain radiation therapy (WBRT)/stereotactic radiosurgery (SRS). Arm 3 will receive cognitive rehabilitation intervention sessions prior to, and concurrent with, WBRT/SRS. Approximately 14 days following WBRT/SRS: all arms will undergo physical and cognitive testing, and: Arm 1 will begin physical activity intervention. Arm 2 will begin physical activity intervention and cognitive intervention. Arm 3 will continue with cognitive intervention and begin physical activity intervention. All Arms will undergo physical and cognitive testing approximately 2.5 months post WBRT/SRS.
The invention discloses a traditional Chinese medicine for treating cold in uterus, a preparation method and application thereof, wherein the pungent and warm cassia twig is adopted to warm yang qi and dispel cold evil; sour and sweet white peony root, radix Paeoniae alba nourishes nutrient-yin, relieves liver urgency and relieves abdominal pain. The ginger is used for warming the stomach and dispelling cold, and the Chinese date is used for tonifying the spleen and replenishing qi. Prepared licorice root, radix Glycyrrhizae Praeparata, as an adjuvant drug, has the effects of replenishing qi to regulate the middle warmer, and harmonizing the effects of the other drugs in the recipe. Wherein cassia twig, pungent and sweet in flavor and capable of resolving yang and warming middle-jiao to tonify spleen deficiency; peony root combined with licorice root, sour and sweet, acts to relieve liver urgency and relieve abdominal pain. The combination of the ingredients can warm the middle-jiao and tonify deficiency and relieve urgency, and has the meaning of nourishing liver and regulating spleen, and benefiting yin and yang, so that the composition can strengthen the middle-jiao and activate yin-yang and qi and blood. The Chinese patent medicine is prepared by extracting, concentrating, mixing thick paste with sucrose powder and dextrin, preparing into granules, and subpackaging into small bags for use. The production process is simple, the production amount is large, and the period is short. The product is dissolved by boiled water when being taken, is taken at a low temperature, has good taste, obvious effect and strong practicability, is not easy to relapse, and is suitable for being widely popularized.
Fluoxetine is first introduced in dose of 20 mg/day and after six weeks the dose is increased to 40 mg/day. If patients have side effects at the dose of 40 mg/day, the dose may be reduced at 20 mg/day. Assessment visits will be conducted at 6 weeks, 3 months, and 6 months of treatment. After 6 months, trial's treatment with fluoxetine is discontinued gradually. A new assessment will be conducted one month after the end of treatment. The expected results are the demonstration of improved scores of the scale UMSARS after 3 and 6 months in the fluoxetine group compared to the placebo group.
BACKGROUND: The use of Complementary and alternative medicine (CAM) in chronic liver disease (CLD) patients in Germany is unknown. This study investigated the frequency of CAM use and associated sociodemographic, clinical and personality factors in CLD patients in Germany.
METHODS: This is a cross-sectional multicenter study of CLD patients attending liver outpatient clinics of university hospitals in Halle(-Saale) and Homburg between 2015 and 2017. Dedicated questionnaires recorded CAM use, sociodemographic and personality factors (evaluated with the "Big five" model, "Hospital Anxiety and Depression"-, "Multidimensional Health Locus of Control"- score). Uni- and multivariate analyses assessed factors associated to CAM use.
RESULTS: Overall 378 patients were recruited, 92 (24.3%) reported to CAM use. On univariate analysis, female CAM users were older (p = 0.001) and more physically active (p = 0.002), male CAM users more often used homeopathy (p = 0.000), actively promoted their health (p = 0.010) or had UDC in their medication (p = 0.004). Logistic regression analysis adjusted for personality factors showed significant association of age, physical exercise (females) and satisfaction with alternative medicine (females, males) to CAM use.
CONCLUSIONS: CAM use is prevalent among CLD patients in Germany and is significantly associated to satisfaction with alternative medicine (females, males), physical exercise and older age (females). Doctors should actively inquire CLD patients about CAM use, as hepatotoxicity or interaction with medication can occur.
Estrogen replacement has been associated with improved learning and memory in both animal and human studies. However, there is some evidence to suggest that "stress" has a detrimental effect on learning for female animals who still have naturally circulating estrogen. Interestingly, when the effects of this hormone are blocked in the body, stress no longer impairs learning. Several investigators have raised the possibility that the physiological response to stress may be exaggerated for women compared to men. Gender differences in biological systems that control the release of gonadal and stress hormones may explain why estrogen is beneficial for women under nonstressed conditions, but detrimental for them under stressed conditions. To date, no study has carefully controlled or manipulated both estrogen use and cortisol levels to further explore this issue. In this placebo-controlled, double blind, parallel-group design clinical study we will evaluate whether estrogen use exacerbates stress-related impairments in cognition for healthy postmenopausal women. Forty subjects will receive either 0.10 mg/day of transdermal beta-estradiol or a placebo skin patch for 8 weeks. In the last week of treatment, subjects will receive 90 mg/day of oral hydrocortisone or a placebo for 4 consecutive days. Scores on tests of memory, attention, and mood, as well as blood levels of estrogen and cortisol will be assessed at baseline, and at weeks 4 and 8. We predict that the estrogen+cortisol combination will have a deleterious effect on cognition and mood relative to the effects of either hormone administered alone. The results of this study are likely to provide important information regarding not only the nature of the interaction between these hormonal systems that occurs in response to stress, but also the conditions under which the beneficial effects of estrogen may be overshadowed.
Wound healing is crucial for survival, prevention of infection, and restoration of tissue function. The immune system drives this process with 3 main phases: inflammation, proliferation, and remodeling. Keloids and hypertrophic scars reveal disruptions in these phases, underscoring the balance needed for healing. Limb amputation, a life-changing event, demands careful consideration for healing and function. Factors such as amputation level, surgical technique, and prosthetic fitting shape outcomes, while complications such as heterotopic ossification challenge recovery. Treatment advances including statins and stem cell therapy hold promise, with dermatologists poised to contribute substantially to postamputation care.
PURPOSE:To obtain a lubricating agent without smell, accidental permeation, swelling and the like with limited deterioration in a condom along with excellent lubricating effect by dissolving polyacrylamide into a small amount of water to be mixed with glycerin. CONSTITUTION:An amount of water for dissolving polyacrylamide is reduced and glycerin is mixed for adjustment of viscosity to obtain a lubricating agent. The viscosity made higher with a reduction in the amount of water for dissolving polyacrylamide is adjusted by glycerin to prevent accidental permeation of a condom allowing the checking the lowering of physical characteristic. Water herein used is a refined water to dissolve polyacrylamide and the amount of water is preferably small with 10-30% of the total. The polyacrylamide herein used is a nonionic high polymer agglutinant using acrylamide (monomer) as a raw material and the viscosity of a solution can be changed by varying the density thereof. It is added at a rate of about 0.2-0.5%. The content of the glycerin is 70-90% and 0.05-0.10% of methylparaben and 0.01-0.03% of propylparaben are added thereto.
The present disclosure is directed to embodiments of a kiosk including a chassis having a patient compartment and a medication compartment. A patient does not have access to the medication compartment in the patient compartment. A dispense structure extends from the patient compartment to the medication compartment such that a dosage of medication may be dispensed to the patient when within the patient compartment. After the medication is dispensed to the patient, a medical professional observes the patient ingest the medication through a video conference display within the patient compartment. A biometric scanner may be in electrical communication with a lock in mechanical cooperation with a door hingedly coupled to the chassis to limit access to the medication compartment. An insulated safe with an internal chamber wherein the internal chamber's temperature is regulated. A medication is stored within the internal chamber of the insulated safe at a selected temperature by regulating the temperature within the internal chamber of the insulated safe.
The present invention relates to a compound capable of providing beneficial effects such as damage repairing and damage preventing, strengthening, water repellent, moisture maintaining, and elasticity and flexibility, etc. by forming a strong covalent bond with a specific residue of a hair, a skin, or a fiber; or a composition containing the same. According to the present invention, the compound or the composition is characterized by using a composition having a functional group by substituting an active part capable of covalent bonding with a residue of a hair, a skin, or a fiber such as thiol, hydroxyl, carboxyl, amine, etc. for polypropylene glycol and/or the terminal end of a polypropylene glycol part existing in natural or synthetic saturated, unsaturated, and branched alkoxylated alcohol, alkoxylated carboxylic acid, alkoxylated (di)amine, or alkoxylated amide compound with two or greater of carbon number of an alkyl part having hydrophobic properties. According to the present invention, the compound or the composition is capable of maintaining moderate moisture in a hair, a skin, and a fiber, etc. by forming the outermost hydrophobic layer; and semi-permanently maintaining the effects.
Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).
PROBLEM TO BE SOLVED: To make it possible to produce silk fibroin powder which has a relatively good adaptability to man, is in a powder form and is, therefore, easily dealable with various kinds of forms of a skin defect part and is easy to handle due to its high apparent density at a low cost by pulverizing non-crystalline fibroin films. SOLUTION: This process for production consists in refining silk fibers, then dissolving the refined fibers into a soln. of an acid or neutral salt. Low- molecular materials are removed by dialysis from this soln., by which an aq. fibroin soln. is obtd. When the silk fibers are dissolved by the acid, the soln. is dialyzed after neutralization with an alkali. The aq. fibroin soln. is spread on a plate and is adhered onto a roll surface to get rid of moisture, by which the film-like fibroin is obtd. The non-crystalline fibroin powder as the wound coating material is obtd. by pulverizing the same. The fibroin powder produced by this method has the relatively high apparatus density and has, therefore, a lower possibility of splashing. The powder is convenient to handle at the time of medical treatment.